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Strengths and limitations of this study
 ► The ascertainment of vital status impacts the validity 
of cancer survival.
 ► This study assessed impact of loss- to- follow- up 
for small populations using Hospital- Based Cancer 
Registries in Japan.
 ► The expected bias was not associated with the 
sample size, but a smaller sample size led to more 
variable bias.
 ► The probable range of the loss- to- follow- up rate 
was simulated without the tendency of incomplete-
ness in the real data.
 ► Survival estimates must be interpreted with caution 
even with small rates of loss- to- follow- up, particu-
larly for smaller samples.
ABSTRACT
Objectives The accuracy of the ascertainment of vital 
status impacts the validity of cancer survival. This study 
assesses the potential impact of loss- to- follow- up on 
survival in Japan, both nationally and in the samples seen 
at individual hospitals.
Design Simulation study
Setting and participants Data of patients diagnosed in 
2007, provided by the Hospital- Based Cancer Registries of 
177 hospitals throughout Japan.
Primary and secondary outcome measures We 
performed simulations for each cancer site, for sample 
sizes of 100, 1000 and 8000 patients, and for loss- to- 
follow- up ranging from 1% to 5%. We estimated the 
average bias and the variation in bias in survival due to 
loss- to- follow- up.
Results The expected bias was not associated with the 
sample size (with 5% loss- to- follow- up, about 2.1% for 
the cohort including all cancers), but a smaller sample 
size led to more variable bias. Sample sizes of around 100 
patients, as may be seen at individual hospitals, had very 
variable bias: with 5% loss- to- follow- up for all cancers, 
25% of samples had a bias of <1.02% and 25% of 
samples had a bias of > 3.06%.
Conclusion Survival should be interpreted with caution 
when loss- to- follow- up is a concern, especially for poor- 
prognosis cancers and for small- area estimates.
BACkgROunD
Survival statistics are the most- used measures 
to estimate cancer patients prognosisand the 
likely course of their disease, and are of great 
interest to patients, clinicians, researchers 
and policy makers.1 Cancer survival estimates 
are employed by policymakers to compare 
cancer outcomes between different popula-
tions and time periods.1 In Japan, the equal-
isation of cancer medical services is a key 
issue for cancer control strategy.2 Hospital- 
level survival estimates would be useful for 
assessing progress toward equalisation of 
services, but interpreting these estimates 
requires an understanding of limitations, 
biases, underlying stochastic processes, and 
clinical and biological insight.3
In Japanese survival statistics of the Hospital- 
Based Cancer Registry (HBCR), data of hospi-
tals that have over 90% of follow- up for their 
cancer patients were used for survival estimates 
(the high- completeness hospitals) in order to 
avoid overestimates of survival, as we do not 
have an official system to link death certificates 
with HBCR data for patients diagnosed before 
2015. Loss- to- follow- up is still a potential limita-
tion of Japanese cancer survival estimates: 
around 5.7% of patients diagnosed in 2007 were 
lost- to- follow- up even in the high- completeness 
hospitals included in the national reporting.4 
The National Cancer Center collects data 
from the HBCR of every designated cancer- 
care hospital, starting with cancer cases diag-
nosed in 2007.4 In the HBCRs, patients’ vital 
status during follow- up is obtained by matching 
hospital databases with resident cards held by 
provincial governments using patients’ names 
and postal addresses and by recording deaths 
occurring in hospital. Loss- to- follow- up may 
occur when patients move around the country 
or when mis- recording of patients’ names or 
postal addresses leads to linkage failure. For 
these patients, survival was censored at their 
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most recent visit to the hospital, an approach giving accu-
rate results only if the reasons they were lost- to- follow- up 
were not related to survival.
Use of cancer survival estimates to assess equalisation 
of cancer medical services naturally involves comparing 
estimates based on the relatively small number of patients 
treated by individual hospitals. Previous studies exploring 
the impact of loss- to- follow- up on survival estimates in a 
large sample (national survival statistics) focused on the 
expected impact5–12 and demonstrated that even modest 
levels of under- registration of deaths might lead to severe 
overestimation of long- term survival. To understand the 
possible impact of loss- to- follow- up on results for small 
areas and individual hospitals, it is important to describe 
the variance of the bias as well as the expected bias. This 
study uses Monte Carlo simulations to assess the impact of 
loss- to- follow- up on Japanese cancer survival estimates for 
different sample sizes to represent the variation resulting 
when reporting at hospital and other scales.
MeThODS
Data source
A subset of incident cases diagnosed in 2007 in the HBCR 
of 177 designated cancer- care hospitals throughout Japan 
was used for the analysis.
The inclusion criteria were:
1. Patients aged 15 years or older at diagnosis.
2. Patients received the first course of treatment at the 
hospital.
a. This prevents duplicate records of patients treated 
at multiple hospitals.
3. Patients had 5 years of complete follow- up after diag-
nosis. Therefore, we only used data of known follow- up 
cases for simulation (complete cases).
In total, 163 084 cancer cases were included: 25 890 
cases for stomach, 20 603 cases for colon and rectum, 
8694 cases for liver, 20 623 cases for lung, 14 764 cases for 
female breast and 72 510 for other cancers. The mean 
age of cancer cases was 68.4 years (SD 10.9) for stomach, 
68.0 years (SD 11.5) for colorectal, 69.0 years (SD 9.6) 
for liver, 69.2 years (SD 10.1) for lung and 58.2 years (SD 
13.0) for female breast.
Data generating mechanism
Sampling with replacement was used to generate 10 000 
datasets for each of the 108 permutations of loss- to- 
follow- up rates, cancer site and sample size discussed 
below.
1. Loss- to- follow- up rate: Loss- to- follow- up rates of 1%, 
2%, 3%, 4% and 5% were considered, as well as an 
empirical estimate based on real loss- to- follow- up rates 
in the high- completeness hospital data of 2007 (6.3% 
for those aged 15–39; 3.8% for 40–49; 2.7% for 50–59; 
2.4% for 60–69; 3.0% for 70–79; and 5.0% for those 
aged 80 or older). When we simulated the loss- to- 
follow- up rate of 1% up to 5%, we randomly selected 
loss- to- follow- up cases across the whole cancer- specific 
cohorts. In age- specific simulations, we selected these 
cases randomly after stratifying by age group.
2. Cancer site: Survival estimates were produced for each 
major cancer site (stomach, colorectal, liver, lung and 
female breast) individually, as well as for all cancers 
combined.
3. Sample size: Samples of 100, 1000 and 8000 patients 
were considered, representing potential incidence at 
different levels of geography (eg, an individual hospi-
tal at 100 patients and Japan at 8000 or more).
Loss- to- follow- up was applied by marking patients identi-
fied as ‘lost to follow- up’ as alive regardless of their true vital 
status. The probability of loss- to- follow- up in this simulation 
study was not related to the survival time of the patient.
Performance measure
We assessed performance using bias in the 5- year survival 
estimate due to loss- to- follow- up; it was calculated as the 
difference between the Kaplan- Meier estimators based on 
the accurate survival data and on the data with loss- to- 
follow- up in each of the 10 000 datasets for each of the 
108 permutations.
The average bias across the 10 000 datasets, the empir-
ical SD and the IQR of the bias were assessed.
All analyses were performed using Stata V.14.0 (Stata 
Corporation).
ReSulTS
Survival for complete cases
The 5- year crude survival rate of all cancers for complete 
cases was 56.6% (95% CI, 56.4% to 56.8%). The 5- year 
crude survival rate for complete cases was 61.5% (95% 
CI, 60.9% to 62.1%) for stomach, 62.9% (95%CI, 62.2% 
to 63.5%) for colorectal, 31.0% (95%CI, 30.1% to 32.0%) 
for liver, 34.0% (95%CI, 33.4% to 34.6%) for lung and 
88.2% (95%CI, 87.6% to 88.7%) for female breast. 
Figure 1 shows the result of simulation of loss- to- follow- up 
rates of 1%, 2%, 3%, 4% and 5%. Figure 2 shows the 
result of simulation of empirical estimates based on real 
loss- to- follow- up rates in the high- completeness hospital 
data of 2007.
Sample size
The expected bias was not associated with the sample size 
(figure 1), but a smaller sample size led to a more variable 
bias. Sample sizes of around 100 patients, as may be seen 
at individual hospitals, had a very variable bias: with 5% 
loss- to- follow- up for all cancers, 25% of samples had a bias 
of <1.02% and 25% of samples had a bias of >3.06%. This 
appears to be exacerbated for sites with poor prognosis 
(figure 1; table 1). In liver cancer, 4.76% of estimates 
have >5%-points of error in samples of 100 patients. With 
larger samples, particularly with 8000 or more cases, the 
variation in bias becomes inconsequential.
loss-to-follow-up rate
Higher loss- to- follow- up rates gave more bias in the survival 
estimates (figure 1; online supplementary appendix table 
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Figure 1 Distribution of bias resulting from 1% up to 5% loss- to- follow- up by different sample sizes.
Figure 2 Distribution of bias resulting from observed rates 
of loss- to- follow- up by different sample size. Empirical 
estimate based on real loss- to- follow- up rates in the high- 
completeness hospital data of 2007 (6.3% for those aged 
15–39; 3.8% for 40–49; 2.7% for 50–59; 2.4% for 60–69; 
3.0% for 70–79; and 5.0% for those aged 80 or older).
1), but had less impact on the spread of the bias. If we 
look at liver cancer, the expected bias with 1% loss- to- 
follow- up in a sample of 1000 was 0.71% with an SD of 
<0.27%, but with 5% loss- to- follow- up it was 3.49% with 
an SD of 0.59%.
Cancer site
Loss- to- follow- up introduced more bias and more variable 
bias for cancer sites with poor prognosis (figures 1 and 2; 
table 1). The expected bias with loss- to- follow- up, similar 
to that observed empirically for lung cancer, was around 
2.12% (SD 0.16%–1.43%), while for breast cancer it was 
only 0.40% (SD 0.07%–0.63%).
DiSCuSSiOn
Loss- to- follow- up rates consistent with those seen in Japan 
in 2007 incidence data lead to highly variable bias in 
survival estimates for small populations. Hospital- level 
survival comparisons should be avoided, as some loss- to- 
follow- up is likely to introduce a large overestimation of 
survival rates for some hospitals but not for others, even 
if the loss- to- follow- up rate is the same for all hospitals. 
Previous studies have demonstrated that higher loss- to- 
follow- up leads to survival estimates with more bias, espe-
cially for cancers with poor prognosis;9 this study also 
found similar trends in both large and small samples.
Our empirical data shows that a higher proportion of 
patients aged 15–39 years and over 80 years were lost to 
follow- up than in other groups. Follow- up currently relies 
on linking patients to their resident card to ascertain their 
vital status. Loss- to- follow- up among younger people may 
be due to patients marrying and changing their names or 
due to moving to other places. Lower follow- up for elderly 
patients may be due to their moving more frequently after 
discharge from the hospital because of difficulties living 
alone, for example, into a nursing home. The number of 
older patients has recently been increasing in the desig-
nated cancer- care hospitals.13 This will make it difficult to 
estimate unbiased survival for cancer patients without any 
official system to follow- up for cancer patients.
Our study has several limitations. First, we considered 
a probable range for the loss- to- follow- up rate for the 
 o
n
 January 29, 2020 by guest. Protected by copyright.
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2019-033510 on 13 January 2020. Downloaded from 
4 Okuyama A, et al. BMJ Open 2020;10:e033510. doi:10.1136/bmjopen-2019-033510
Open access 
Table 1 Summary results across 10 000 simulations for each cancer site, with loss- to- follow- up probabilities by age group 
based on those seen in real data
Cancer site
‘True’ 5- year 
survival rate (%)
Loss- to- 
follow- up
Sample 
size
Expected 
bias (%)
SD of the 
bias (%)
IQR of bias 
(%)
Percentage with bias of 
5%-points or more (%)
All 56.6 Real 100 1.45 1.19 1.00–2.00 1.30
All 56.6 Real 1000 1.45 0.38 1.20–1.70 <0.01
All 56.6 Real 8000 1.44 0.13 1.35–1.53 <0.01
Breast 88.2 Real 100 0.40 0.63 0.00–1.00 0.01
Breast 88.2 Real 1000 0.40 0.20 0.30–0.50 <0.01
Breast 88.2 Real 8000 0.40 0.07 0.35–0.45 <0.01
Colon 62.9 Real 100 1.28 1.11 0.00–2.00 0.82
Colon 62.9 Real 1000 1.26 0.35 1.00–1.50 <0.01
Colon 62.9 Real 8000 1.26 0.12 1.18–1.35 <0.01
Liver 31.0 Real 100 2.16 1.44 1.00–3.00 4.76
Liver 31.0 Real 1000 2.15 0.46 1.80–2.50 <0.01
Liver 31.0 Real 8000 2.15 0.16 2.04–2.26 <0.01
Lung 34.0 Real 100 2.11 1.43 1.00–3.00 4.18
Lung 34.0 Real 1000 2.12 0.46 1.80–2.40 <0.01
Lung 34.0 Real 8000 2.12 0.16 2.01–2.22 <0.01
Stomach 61.5 Real 100 1.29 1.12 0.00–2.00 0.88
Stomach 61.5 Real 1000 1.29 0.36 1.00–1.50 <0.01
Stomach 61.5 Real 8000 1.29 0.13 1.20–1.38 <0.01
*Real loss- to- follow- up means that empirical estimate based on real loss- to- follow- up rates in the high- completeness hospital data of 2007 
(6.3% for those aged 15–39; 3.8% for 40–49; 2.7% for 50–59; 2.4% for 60–69; 3.0% for 70–79 and 5.0% for those aged 80 or older).
simulation work. We do not know the incompleteness of 
death ascertainment in the real data, which may affect the 
true survival rate used as a baseline, and so we cannot esti-
mate true survival from this simulation. Second, we used 
data for patients diagnosed in 2007. This data is the data 
collected in first year in Japan by HBCR. Cancer registries 
may have lacked experience gathering data items needed 
to estimate survival, and some data, such as follow- up- 
days or last- contact date, may have been miss- recorded. 
Third, when patients are known to be lost- to- follow- up in 
real data, their survival is censored at the date they were 
last known to have been alive. Such loss- to- follow- up is 
likely to be informative censoring, and our results could 
be viewed as an approximate upper bound on the bias. 
Finally, this simulation only considers absolute survival. 
Previous studies report that, in general, relative survival is 
much more affected by incomplete registration of deaths 
than absolute survival, and potential problems are much 
larger for relative survival estimates in older patients 
compared with younger.7 Even more care will be needed 
when interpreting relative survival estimates.
COnCluSiOn
Loss- to- follow- up of the level currently observed in 
HBCR in designated cancer- care hospitals in Japan intro-
duces substantial and variable bias into cancer survival 
estimates for small samples. Until we achieve >99% 
completeness in ascertainment of survival status, we must 
interpret survival estimates with caution, particularly for 
smaller samples (eg, individual hospitals). An official 
follow- up system is required to support unbiased estima-
tion of survival.
Patient and public involvement
This study is based on historical hospital- level data 
collected for the purpose of national disease registra-
tion. The research question and outcome measures are 
aimed at assessing standard epidemiological outputs, and 
patients were not involved in this study.
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